Pfizer PFE agrees to settle Depo-Provera litigation for over $1.2 billion
Pfizer has agreed to settle Depo-Provera birth-control litigation involving an estimated 5,000 claims worth more than $1.2 billion in aggregate, according to mass-tort funding company Legal Bay, with terms still confidential. The settlement adds a material legal overhang to Pfizer, whose FY2025 revenue was $62.6B and declined 1.6% year over year, but the ultimate earnings impact cannot yet be assessed.
PR NEWSWIRE / FILEThe story
Legal Bay LLC, a pre-settlement funding company, reported that Pfizer agreed to resolve Depo-Provera birth-control litigation. The company estimates that approximately 5,000 claims could be covered by the settlement, with an aggregate value exceeding $1.2 billion. The report was issued on Aug. 18, 2026, and the settlement terms remain confidential.
The reported agreement directly affects Pfizer, which generated $62.6B of revenue in FY2025, down 1.6% year over year, with a 12.4% net margin and $1.36 diluted EPS. The disclosed claim estimate and aggregate value provide scale, but there is no information here on Pfizer's cash contribution, insurance recoveries, accounting treatment, or timing.
The next items to watch are confirmation from Pfizer or court filings, the final number of resolved claims, and disclosure of the settlement's financial terms. Until those details emerge, the legal headline is clearer than its effect on reported earnings or cash flow.
Our read · Tue, Aug 18
The reported Depo-Provera settlement moves the near-term risk to the downside for PFE, while confidential terms leave the earnings hit unquantified.
Why. The immediate pressure is legal-uncertainty expansion against a business already showing FY2025 revenue of $62.6B, down 1.6% year over year; a settlement exceeding $1.2 billion could weigh on cash flow or earnings once terms are disclosed. The read is limited by the absence of confirmed terms, insurance recoveries, and accounting treatment, so the setup is a headline-driven downside trade rather than a fully quantified fundamental break.
Both cases
What could change this view: Pfizer confirmation could show limited net exposure, insurance coverage, or accounting treatment that makes the reported aggregate value less financially damaging than the headline implies.
Who reported it · 1
Keep reading
Latest on the Wire
Bitcoin nears $64,000 as Anthropic IPO lifts Nasdaq futures nearly 2%UniCredit reaches agreement with Berlin over Commerzbank takeoverAustralia’s jobless rate hits 5-year high, markets ramp up rate-cut bets for 2027Trump meets Putin and Xi separately ahead of historic three-way talksHyperscale Data warns of $74.8 million gap for Michigan AI projectContinue on the Wire →Latest on the Wire
Hyperscale Data warns of $74.8 million gap for Michigan AI projectMeta pauses plan to give Zuckerberg new shares without losing controlFed releases October meeting minutes three weeks after policy decisionAnthropic Said to Guide IPO Pricing Above Market RangeContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookNvidia interim CEO Colette Kress faces first earnings test after HuangNvidia CEO Jensen Huang reportedly resigns as US-China tensions riseNvidia CFO Colette Kress to serve as interim CEO after Jensen HuangAbout this report
Reported by PR Newswire as Legal Bay Pre-Settlement Funding Reports Pfizer Agrees to Settle Depo-Provera Birth Control Litigation
, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →